Brief: Catalyst Biosciences Says On Dec 13, Co Entered Into Amended & Restated License Agreement Effective As Of Dec 17, 2018, With Isu Abxis

ISU ABXIS

18/12/2018 23:35

Dec 18 (Reuters) - CATALYST BIOSCIENCES:
    * CATALYST BIOSCIENCES - ON DEC 13, 2018, CO ENTERED INTO AN
AMENDED AND RESTATED LICENSE AGREEMENT EFFECTIVE AS OF DEC 17,
2018, WITH ISU ABXIS
    * CATALYST BIOSCIENCES - AGREEMENT AMENDS AND RESTATES IN
FULL
CO'S LICENSE AND COLLABORATION AGREEMENT WITH ISU, DATED AS OF
SEPT 16, 2013
    * CATALYST BIOSCIENCES - PURSUANT TO A&R AGREEMENT, ISU WILL
RECEIVE COMMERCIALIZATION RIGHTS IN SOUTH KOREA TO DALCINONACOG
ALFA
    * CATALYST BIOSCIENCES- AGREEMENT ELIMINATES PROFIT SHARING
ARRANGEMENT IN ORIGINAL AGREEMENT & PROVIDES FOR A LOW
SINGLE-DIGIT ROYALTY PAYMENT TO ISU
    * CATALYST BIOSCIENCES - PER AGREEMENT, CO TO MAKE UP TO
$2.5
MILLION REGULATORY & DEVELOPMENT MILESTONE PAYMENTS TO ISU, IF
APPLICABLE MILESTONES MET
    * CATALYST BIOSCIENCES - AS PER AGREEMENT, CO WILL ALSO MAKE
UP TO
$17 MILLION IN COMMERCIAL MILESTONE PAYMENTS TO ISU, IF
APPLICABLE MILESTONES ARE MET

Source text: (https://bit.ly/2Gti30a)
Further company coverage:  CBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))